Abstract:Signaling through the Rho family of small GTPases has been increasingly investigated for their involvement in a wide variety of diseases such as cardiovascular, pulmonary, and neurological disorders as well as cancer. Rho GTPases are a subfamily of the Ras superfamily proteins which play essential roles in a number of biological processes, especially in the regulation of cell shape change, cytokinesis, cell adhesion, and cell migration. Many of these processes demonstrate a common theme: the rapid and dynamic reorganization of actin cytoskeleton of which Rho signaling has now emerged as a major switch control. The involvement of dynamic changes of Rho GTPases in disease states underscores the need to produce effective inhibitors for their therapeutic applications. Fasudil and Y-27632, with many newer additions, are two classes of widely used chemical compounds that inhibit Rho kinase (ROCK), an important downstream effector of RhoA subfamily GTPases. These inhibitors have been successful in many preclinical studies, indicating the potential benefit of clinical Rho pathway inhibition. On the other hand, except for Rac1 inhibitor NSC23766, there are few effective inhibitors directly targeting Rho GTPases, likely due to the lack of optimal structural information on individual Rho-RhoGEF, Rho-RhoGAP, or Rho-RhoGDI interaction to achieve specificity. Recently, LM11A-31 and other derivatives of peptide mimetic ligands for p75 neurotrophin receptor (p75(NTR)) show promising effects upstream of Rho GTPase signaling in neuronal regeneration. CCG-1423, a chemical compound showing profiles of inhibiting downstream of RhoA, is a further attempt for the development of novel pharmacological tools to disrupt Rho signaling pathway in cancer. Because of a rapidly growing number of studies deciphering the role of the Rho proteins in many diseases, specific and potent pharmaceutical modulators of various steps of Rho GTPase signaling pathway are critically needed to target for therapeutic intervention in cardiovascular disease, neurological disorders, and cancer progression.

Rho/ROCK and Neurological Diseases

ROCK in CNS: Different Roles of Isoforms and Therapeutic Target for Neurodegenerative Disorders

Distinct Roles of ROCK1 and ROCK2 on the Cerebral Ischemia Injury and Subsequently Neurodegenerative Changes

ROCK inhibition in models of neurodegeneration and its potential for clinical translation

Neuroproteomics approach and neurosystems biology analysis: ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma

Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges

Small guanine nucleotide-binding protein Rho and myocardial function

Advances in the Development of Rho-associated Protein Kinase (ROCK) Inhibitors.

Signaling Through Rho GTPase Pathway As Viable Drug Target.

Rho/Rho-associated Kinase Pathway in Glaucoma (Review).

RhoA-ROCK Signaling as a Therapeutic Target in Traumatic Brain Injury

ROCK inhibitor: Focus on recent updates

RhoA/Rho-kinase in the Cardiovascular System

Rho signaling pathway targeted to promote spinal cord repair

A critical role of Rho-kinase ROCK2 in the regulation of spine and synaptic function.

Progress of the study of rho-kinase and future perspective of the inhibitor

Rho signaling research: history, current status and future directions

Y-39983 downregulates RhoA/Rho-associated kinase expression during its promotion of axonal regeneration.

Rhoa/ROCK, mTOR and Secretome-Based Treatments for Ischemic Stroke: New Perspectives

RhoA Signaling in Neurodegenerative Diseases